The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Evergreening, patent challenges, and effective market life in pharmaceuticals
Open accessAbstract
Observers worry that generic patent challenges are on the rise and reduce the effective market life of drugs. A related concern is that challenges disproportionately target high-sales drugs, reducing market life for these "blockbusters." To study these questions, we examine new data on generic entry over the past decade. We show that challenges are more common for higher sales drugs. We also demonstrate a slight increase in challenges over this period, and a sharper increase for early challenges. Despite this, effective market life is stable across drug sales categories, and has hardly changed over the decade. To better understand these results, we examine which patents are challenged on each drug, and show that lower quality and later expiring patents disproportionately draw challenges. Overall, this evidence suggests that challenges serve to maintain, not reduce, the historical baseline of effective market life, thereby limiting the effectiveness of "evergreening" by branded firms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2001) · RePEc: Research Papers in Economics · Cited by 27,577
Rising Above The Gathering Storm: Energizing and Employing America for a Brighter Economic Future
Augustine, N. R. (2006) · Cited by 2,064
Jaffe, A. B., & Lerner, J. (2011) · Princeton University Press eBooks · doi:10.1515/9781400837342 · Cited by 678
Ammendola, G. (2005) · American Foreign Policy Interests · doi:10.1080/10803920490970043 · Cited by 475
Longer Patents for Increased Generic Competition in the US
Grabowski, H. G., & Vernon, J. (1996) · PharmacoEconomics · doi:10.2165/00019053-199600102-00017 · Cited by 140
The Ongoing Regulation of Generic Drugs
Frank, R. G. (2007) · New England Journal of Medicine · doi:10.1056/nejmp078193 · Cited by 137
Regulation and welfare: evidence from paragraph IV generic entry in the pharmaceutical industry
Branstetter, L., Chatterjee, C., & Higgins, M. J. (2016) · The RAND Journal of Economics · doi:10.1111/1756-2171.12157 · Cited by 125
Regulation and Welfare: Evidence from Paragraph IV Generic Entry in the Pharmaceutical Industry
Branstetter, L., Chatterjee, C., & Higgins, M. J. (2011) · National Bureau of Economic Research · doi:10.3386/w17188 · Cited by 100
When Do Generics Challenge Drug Patents?
Hemphill, C. S., & Sampat, B. N. (2011) · Journal of Empirical Legal Studies · doi:10.1111/j.1740-1461.2011.01235.x · Cited by 98
Self-citationBalancing Innovation and Access: Patent Challenges Tip the Scales
Higgins, M. J., & Graham, S. J. H. (2009) · Science · doi:10.1126/science.1176116 · Cited by 96
Cited by
Public R&D Investments and Private-sector Patenting: Evidence from NIH Funding Rules
Azoulay, P., Graff Zivin, J. S., Li, D., & Sampat, B. N. (2019) · The Review of Economic Studies · doi:10.1093/restud/rdy034 · Cited by 349
Self-citationDo Firms Underinvest in Long-Term Research? Evidence from Cancer Clinical Trials
Budish, E., Roin, B. N., & Williams, H. (2015) · American Economic Review · doi:10.1257/aer.20131176 · Cited by 302
The applied value of public investments in biomedical research
Li, D., Azoulay, P., & Sampat, B. N. (2017) · Science · doi:10.1126/science.aal0010 · Cited by 194
Self-citationThe promise and challenges of drug repurposing in psychiatry
Fava, M. (2018) · World Psychiatry · doi:10.1002/wps.20481 · Cited by 40
Metadata
- Authors
- Hemphill, C. S., & Sampat, B. N.
- Venue
- Journal of Health Economics
- Publisher
- Elsevier BV
- Published
- 2012-03
- Volume
- 31
- Issue
- 2
- Pages
- 327-339
- ISSN
- 0167-6296 (ISSN-L)
- OpenAlex
- W3124325052
- Cited by
- 262
- References
- 14
- FWCI
- 44.69
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evergreening, patent challenges, and effective market life in pharmaceuticals. https://app.cochat.ai/papers/10.1016/j.jhealeco.2012.01.004
- The paper
- Hemphill, C. S., & Sampat, B. N. (2012). Evergreening, patent challenges, and effective market life in pharmaceuticals. Journal of Health Economics. https://doi.org/10.1016/j.jhealeco.2012.01.004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.